16 September 2026 editorial review · Item
NPH insulin (isophane / Humulin N / Novolin N): review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Thriving evidence review — 16 September 2026
Record: NPH insulin (isophane / Humulin N / Novolin N)
Scope and findings:
- Read current HumulinN and NovolinN labels: intermediate action,median Humulin maximal glucose effect6.5h(range2.8–13),variable Novolin duration up to 24h,onset1–2h; resuspension/storage product-specific. Unqualified cheapest claim softened because prices and coverage vary.
Primary sources checked:
Limits: The review is restricted to the scopes above. Historical efficacy estimates, editorial scoring and country-specific access were not fully reverified unless expressly stated. A manufacturer or conference report retains that evidence level.